Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma.

Long Zhang, Yingying Yang, Haojie Zhou, Qingmei Zheng, Yuhao Li, Shansong Zheng, Shuyong Zhao, Dong Chen, Chuanwen Fan, Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. European Journal of Medicinal Chemistry. ,vol. 102, pp. 445- 463 ,(2015) , 10.1016/J.EJMECH.2015.08.026

Erminia Massarelli, Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer Lung Cancer, Fourth Edition. pp. 421- 434 ,(2014) , 10.1002/9781118468791.CH27

Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854

Sandra W Cowan-Jacob, Wolfgang Jahnke, Stefan Knapp, Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases Future Medicinal Chemistry. ,vol. 6, pp. 541- 561 ,(2014) , 10.4155/FMC.13.216

D. Ross Camidge, William Pao, Lecia V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer Nature Reviews Clinical Oncology. ,vol. 11, pp. 473- 481 ,(2014) , 10.1038/NRCLINONC.2014.104

Daniel Morgensztern, Ramaswamy Govindan, Is there a role for cetuximab in non-small cell lung cancer? Clinical Cancer Research. ,vol. 13, ,(2007) , 10.1158/1078-0432.CCR-07-0545

Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson, William Pao, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discovery. ,vol. 4, pp. 1046- 1061 ,(2014) , 10.1158/2159-8290.CD-14-0337

Julian Engel, André Richters, Matthäus Getlik, Stefano Tomassi, Marina Keul, Martin Termathe, Jonas Lategahn, Christian Becker, Svenja Mayer-Wrangowski, Christian Grütter, Niklas Uhlenbrock, Jasmin Krüll, Niklas Schaumann, Simone Eppmann, Patrick Kibies, Franziska Hoffgaard, Jochen Heil, Sascha Menninger, Sandra Ortiz-Cuaran, Johannes M. Heuckmann, Verena Tinnefeld, René P. Zahedi, Martin L. Sos, Carsten Schultz-Fademrecht, Roman K. Thomas, Stefan M. Kast, Daniel Rauh, Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach Journal of Medicinal Chemistry. ,vol. 58, pp. 6844- 6863 ,(2015) , 10.1021/ACS.JMEDCHEM.5B01082

Maria E. Arcila, Khedoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris A. Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi, EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Molecular Cancer Therapeutics. ,vol. 12, pp. 220- 229 ,(2013) , 10.1158/1535-7163.MCT-12-0620

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vnencak-Jones, Lynne Berry, Yumei Pan, Hidefumi Sasaki, Jeffrey A. Engelman, Edward B. Garon, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn, William Pao, Characteristics of Lung Cancers Harboring NRAS Mutations Clinical Cancer Research. ,vol. 19, pp. 2584- 2591 ,(2013) , 10.1158/1078-0432.CCR-12-3173